Fed-up MD Anderson oncologist jumps on social media to fight drug prices. Flush with success in negotiating discounts for hepatitis C drugs, payers are promising to strong-arm drugmakers in other treatment classes, too–cholesterol and cancer, for instance. They’ll have more… Continue Reading
While startups like Uber and Snapchat have garnered giant valuations recently, another sector looks like it might be getting just as overheated. Big pharma firms and investors have been showering billions on speculative companies that have never produced a viable drug. For four years… Continue Reading
The 2015 Harris corporate reputation poll is out and the news for Big Pharma isn’t good, to say the least. In the poll—which measures the “reputation quotient” of the most visible American companies among the general public—Big Pharma ranked ninth… Continue Reading